HC Wainwright Weighs in on Travere Therapeutics, Inc.’s FY2025 Earnings (NASDAQ:TVTX)

Travere Therapeutics, Inc. (NASDAQ:TVTX) – HC Wainwright cut their FY2025 EPS estimates for Travere Therapeutics in a research note issued to investors on Wednesday, April 24th. HC Wainwright analyst E. Arce now expects that the company will post earnings of ($1.80) per share for the year, down from their previous forecast of ($1.71). HC Wainwright has a “Buy” rating and a $19.00 price objective on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.10) per share. HC Wainwright also issued estimates for Travere Therapeutics’ FY2026 earnings at $0.20 EPS and FY2027 earnings at $1.98 EPS.

TVTX has been the subject of several other research reports. Wells Fargo & Company upped their price target on shares of Travere Therapeutics from $8.00 to $9.00 and gave the stock an “equal weight” rating in a research report on Friday, February 16th. Guggenheim restated a “neutral” rating on shares of Travere Therapeutics in a research report on Wednesday, March 27th. Piper Sandler upped their price target on shares of Travere Therapeutics from $10.00 to $11.00 and gave the stock a “neutral” rating in a research report on Thursday, January 18th. Finally, Wedbush restated an “outperform” rating and set a $13.00 price target on shares of Travere Therapeutics in a research report on Wednesday, April 17th. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Travere Therapeutics Stock Down 2.4 %

Travere Therapeutics stock opened at $5.26 on Friday. The company has a 50-day simple moving average of $7.28 and a 200-day simple moving average of $7.65. The firm has a market capitalization of $400.33 million, a P/E ratio of -3.27 and a beta of 0.58. The company has a debt-to-equity ratio of 1.88, a quick ratio of 3.41 and a current ratio of 3.47. Travere Therapeutics has a one year low of $5.12 and a one year high of $22.75.

Travere Therapeutics (NASDAQ:TVTX) last released its earnings results on Thursday, February 15th. The company reported ($1.16) earnings per share for the quarter, beating the consensus estimate of ($1.27) by $0.11. The firm had revenue of $45.06 million during the quarter, compared to analyst estimates of $41.25 million. Travere Therapeutics had a negative net margin of 56.02% and a negative return on equity of 177.97%.

Institutional Trading of Travere Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Teacher Retirement System of Texas lifted its stake in Travere Therapeutics by 9.6% during the third quarter. Teacher Retirement System of Texas now owns 18,804 shares of the company’s stock valued at $168,000 after buying an additional 1,641 shares in the last quarter. Arizona State Retirement System lifted its stake in Travere Therapeutics by 9.7% during the fourth quarter. Arizona State Retirement System now owns 20,969 shares of the company’s stock valued at $189,000 after buying an additional 1,851 shares in the last quarter. Signaturefd LLC lifted its stake in Travere Therapeutics by 1,656.4% during the fourth quarter. Signaturefd LLC now owns 3,021 shares of the company’s stock valued at $27,000 after buying an additional 2,849 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Travere Therapeutics by 7.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 46,424 shares of the company’s stock valued at $417,000 after buying an additional 3,083 shares in the last quarter. Finally, Rice Hall James & Associates LLC lifted its stake in Travere Therapeutics by 4.5% during the first quarter. Rice Hall James & Associates LLC now owns 73,400 shares of the company’s stock valued at $566,000 after buying an additional 3,140 shares in the last quarter.

Insider Buying and Selling at Travere Therapeutics

In other Travere Therapeutics news, CFO Christopher R. Cline sold 3,818 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $8.53, for a total value of $32,567.54. Following the completion of the sale, the chief financial officer now directly owns 70,903 shares of the company’s stock, valued at approximately $604,802.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Travere Therapeutics news, SVP William E. Rote sold 4,764 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $8.71, for a total transaction of $41,494.44. Following the completion of the sale, the senior vice president now directly owns 80,720 shares of the company’s stock, valued at $703,071.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Christopher R. Cline sold 3,818 shares of the company’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $8.53, for a total transaction of $32,567.54. Following the sale, the chief financial officer now directly owns 70,903 shares of the company’s stock, valued at $604,802.59. The disclosure for this sale can be found here. In the last three months, insiders sold 34,773 shares of company stock valued at $300,625. 3.75% of the stock is owned by insiders.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.